BR0213143A - Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno - Google Patents
Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquilenoInfo
- Publication number
- BR0213143A BR0213143A BR0213143-9A BR0213143A BR0213143A BR 0213143 A BR0213143 A BR 0213143A BR 0213143 A BR0213143 A BR 0213143A BR 0213143 A BR0213143 A BR 0213143A
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- block copolymer
- oral
- polyoxyalkylene block
- administration containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSIçõES LìQUIDAS PARA ADMINISTRAçãO ORAL CONTENDO GUAIFENESINA E UM COPOLìMERO DE BLOCO POLIOXIALQUILENO". A presente invenção refere-se a uma composição farmacêutica líquida para administração oral que demonstra excelente estabilidade física ao mesmo tempo em que transporta níveis concentrados de ativo(s) farmacêutico(s). Especificamente, estas composições não permitem que o ativo sofra precipitação ou decantação, mesmo por longos períodos de tempo, separando-se da solução. Entre as vantagens desta invenção está o fato de que as composições não necessitam ser submetidas à agitação antes do uso, como método para ressuspender ou dissolver o material ativo de droga a fim de assegurar uma dosagem uniforme e consistente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/974,347 US7138133B2 (en) | 2001-10-10 | 2001-10-10 | Orally administered liquid compositions |
PCT/US2002/030641 WO2003030877A1 (en) | 2001-10-10 | 2002-09-27 | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213143A true BR0213143A (pt) | 2004-11-30 |
Family
ID=25521922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213143-9A BR0213143A (pt) | 2001-10-10 | 2002-09-27 | Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno |
Country Status (15)
Country | Link |
---|---|
US (1) | US7138133B2 (pt) |
EP (1) | EP1438031B1 (pt) |
JP (1) | JP2005505590A (pt) |
CN (1) | CN1314451C (pt) |
AT (1) | ATE409026T1 (pt) |
AU (1) | AU2002327744B2 (pt) |
BR (1) | BR0213143A (pt) |
CA (1) | CA2462606C (pt) |
DE (1) | DE60229063D1 (pt) |
ES (1) | ES2314089T3 (pt) |
MX (1) | MXPA04003304A (pt) |
PL (1) | PL203209B1 (pt) |
RU (1) | RU2281087C2 (pt) |
WO (1) | WO2003030877A1 (pt) |
ZA (1) | ZA200402046B (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050249802A1 (en) * | 2004-05-06 | 2005-11-10 | The Procter & Gamble Company | Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients |
US20070020330A1 (en) * | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
DK2522365T3 (en) | 2004-11-24 | 2017-02-06 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and methods for its use |
US20090004231A1 (en) | 2007-06-30 | 2009-01-01 | Popp Shane M | Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring |
BRPI0819338A2 (pt) | 2007-11-21 | 2015-05-19 | Procter & Gamble | Preparações, métodos e kits úteis para o tratamento de tosse |
US9585973B1 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
GB2477545B (en) * | 2010-02-05 | 2011-12-21 | Special Products Ltd | A liquid morphine composition for buccal administration |
EA025640B1 (ru) * | 2010-07-12 | 2017-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Водная композиция, содержащая бромгексин |
AU2011347257A1 (en) | 2010-12-23 | 2013-05-23 | Lectio Pharmaentwicklungs- Und Verwertungs Gmbh | Aqueous solution of ambroxol |
JP5954676B2 (ja) * | 2011-03-21 | 2016-07-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アンブロキソールを含む固体製剤 |
WO2012135422A2 (en) * | 2011-04-01 | 2012-10-04 | University Of Florida Research Foundation, Inc. | Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US20150133533A1 (en) * | 2012-05-08 | 2015-05-14 | Mahesh Kandula | Compositions and methods for the treatment of cough |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
CN104603100A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗炎症性肠病的组合物和方法 |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
CA2873098A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016110865A1 (en) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
CN104224765B (zh) * | 2014-09-03 | 2016-08-24 | 河北仁合益康药业有限公司 | 一种愈酚溴新口服溶液组合物 |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9549907B1 (en) * | 2015-11-13 | 2017-01-24 | Sovereign Pharmaceuticals, Llc | Immediate release oral guaifenesin solution |
CA3045118A1 (en) * | 2016-11-28 | 2018-05-31 | Johnson & Johnson Consumer Inc. | Liquid compositions comprising a mucoadhesive agent |
WO2024005758A1 (en) * | 2022-06-29 | 2024-01-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | A stable oral liquid composition comprising terbutaline & guaifenesin |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4511563A (en) | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
IL79552A0 (en) | 1985-07-30 | 1986-10-31 | Int Minerals & Chem Corp | Stabilization of growth promoting hormones |
DE3532562A1 (de) | 1985-09-12 | 1987-03-12 | Dolorgiet Gmbh & Co Kg | Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
US5030448A (en) | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5071643A (en) | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
US4810503A (en) | 1987-03-31 | 1989-03-07 | Basf Corporation | Polymers which form gels at low concentrations in water |
JP2627158B2 (ja) * | 1987-11-20 | 1997-07-02 | ゼリア新薬工業株式会社 | 脂溶性物質の安定な水溶液 |
US4911926A (en) | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
US5681576A (en) | 1988-11-16 | 1997-10-28 | Mdv Technologies, Inc. | Method and composition for post surgical adhesion reduction |
US5135751A (en) | 1988-11-16 | 1992-08-04 | Mediventures Incorporated | Composition for reducing postsurgical adhesions |
CA2011423A1 (en) | 1989-03-07 | 1990-09-07 | Peter M. Taylor | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
US5100898A (en) | 1990-01-25 | 1992-03-31 | Richardson-Vicks Inc. | Antitussive liquid compositions containing dyclonine |
US5300295A (en) | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
US5298260A (en) | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5143731A (en) | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US5183669A (en) * | 1991-05-28 | 1993-02-02 | Guillemette A Roger | Deflector for crosshead extruder |
US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
EP0551626A1 (en) | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
US5505961A (en) | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
CN1106259A (zh) | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂 |
IT1274026B (it) | 1994-03-01 | 1997-07-14 | Acraf | Composizione antitosse |
US5510389A (en) | 1994-03-02 | 1996-04-23 | The Procter & Gamble Company | Concentrated acetaminophen solution compositions |
KR0163563B1 (ko) | 1994-03-23 | 1998-12-01 | 김종인 | 피부질환 치료용 의약조성물 |
JPH11502839A (ja) | 1995-03-29 | 1999-03-09 | ザ、プロクター、エンド、ギャンブル、カンパニー | 鎮咳剤マイクロカプセル |
KR0180334B1 (ko) | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
AU1526497A (en) | 1995-10-06 | 1998-07-31 | Mdv Technologies, Inc. | Method and non-gelling composition for inhibiting post-surgical adhesions |
DE19545043A1 (de) | 1995-12-02 | 1997-06-05 | Scherer Gmbh R P | Pharmazeutische Präparate zur oralen Anwendung und Verfahren zu ihrer Herstellung |
AU1332997A (en) | 1995-12-11 | 1997-07-03 | Mdv Technologies, Inc. | Ophthalmic composition comprising polyoxyethylene-polyoxypropylene polymers |
US5869082A (en) | 1996-04-12 | 1999-02-09 | Flemington Pharmaceutical Corp. | Buccal, non-polar spray for nitroglycerin |
ATE288255T1 (de) | 1996-04-12 | 2005-02-15 | Novadel Pharma Inc | Polares bukkales spray |
US5955098A (en) | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
SE9601528D0 (sv) | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as antitissue agent |
JP2000516614A (ja) | 1996-08-12 | 2000-12-12 | メドロジック グローバル コーポレーション | 製薬適用用組成物 |
US6290986B1 (en) * | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US5820854A (en) | 1997-03-27 | 1998-10-13 | The Procter & Gamble Company | Oral compositions containing polyoxyethylene |
DE69738333T2 (de) | 1997-10-01 | 2008-11-27 | Novadel Pharma Inc. | Nichtpolares Spray zur bukkalen Verabreichung |
EP1039932A1 (en) | 1997-12-23 | 2000-10-04 | Alliance Pharmaceutical Corporation | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
GB9822170D0 (en) | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
US6846495B2 (en) | 1999-01-11 | 2005-01-25 | The Procter & Gamble Company | Compositions having improved delivery of actives |
ES2282134T3 (es) | 1999-09-11 | 2007-10-16 | THE PROCTER & GAMBLE COMPANY | Copolimeros de polioxialquileno que contienen vehiculos liquidos fluidos. |
CN1211085C (zh) * | 1999-09-29 | 2005-07-20 | 宝洁公司 | 稳定性改善的组合物 |
-
2001
- 2001-10-10 US US09/974,347 patent/US7138133B2/en not_active Expired - Fee Related
-
2002
- 2002-09-27 CA CA002462606A patent/CA2462606C/en not_active Expired - Fee Related
- 2002-09-27 MX MXPA04003304A patent/MXPA04003304A/es active IP Right Grant
- 2002-09-27 JP JP2003533909A patent/JP2005505590A/ja active Pending
- 2002-09-27 ES ES02763751T patent/ES2314089T3/es not_active Expired - Lifetime
- 2002-09-27 WO PCT/US2002/030641 patent/WO2003030877A1/en active Application Filing
- 2002-09-27 AT AT02763751T patent/ATE409026T1/de not_active IP Right Cessation
- 2002-09-27 RU RU2004114225/15A patent/RU2281087C2/ru not_active IP Right Cessation
- 2002-09-27 PL PL370068A patent/PL203209B1/pl unknown
- 2002-09-27 EP EP02763751A patent/EP1438031B1/en not_active Expired - Lifetime
- 2002-09-27 BR BR0213143-9A patent/BR0213143A/pt not_active Application Discontinuation
- 2002-09-27 CN CNB028198905A patent/CN1314451C/zh not_active Expired - Fee Related
- 2002-09-27 AU AU2002327744A patent/AU2002327744B2/en not_active Ceased
- 2002-09-27 DE DE60229063T patent/DE60229063D1/de not_active Expired - Lifetime
-
2004
- 2004-03-15 ZA ZA200402046A patent/ZA200402046B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2281087C2 (ru) | 2006-08-10 |
EP1438031B1 (en) | 2008-09-24 |
WO2003030877A1 (en) | 2003-04-17 |
CA2462606A1 (en) | 2003-04-17 |
EP1438031A1 (en) | 2004-07-21 |
RU2004114225A (ru) | 2005-04-20 |
US20030113377A1 (en) | 2003-06-19 |
AU2002327744B2 (en) | 2006-10-12 |
PL203209B1 (pl) | 2009-09-30 |
MXPA04003304A (es) | 2004-07-23 |
JP2005505590A (ja) | 2005-02-24 |
ES2314089T3 (es) | 2009-03-16 |
PL370068A1 (en) | 2005-05-16 |
ATE409026T1 (de) | 2008-10-15 |
CA2462606C (en) | 2009-08-04 |
CN1314451C (zh) | 2007-05-09 |
CN1564679A (zh) | 2005-01-12 |
US7138133B2 (en) | 2006-11-21 |
DE60229063D1 (de) | 2008-11-06 |
ZA200402046B (en) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0213143A (pt) | Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno | |
TR200101927T2 (tr) | Etkin maddelerin geliştirilmiş bir şekilde verilmesini sağlayan bileşimler. | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
CY1110264T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν ευαισθητα σε ρη συμπολυμερη τυπου μπλοκ και υδροφοβο φαρμακο | |
ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
AR037996A1 (es) | Compuesto derivado de amino nicotinato, composicion farmaceutica; proceso para su preparacion y su uso como medicamento | |
CY1115707T1 (el) | Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων | |
AR052153A1 (es) | Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos | |
DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
NO20062051L (no) | Farmasoytisk virkestoffinneholdende formulering med belegg | |
MA34296B1 (fr) | Composition retard injectable antipsychotique | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
ATE332138T1 (de) | Flibanserin zur behandlung extrapyramidaler bewegungsstörungen | |
EA200501702A1 (ru) | Устойчивая к манипуляциям дозировочная форма для трансдермального введения | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
DK1885333T3 (da) | Farmaceutisk formulering af apomorphin til bukkal indgivelse | |
FR2878161B1 (fr) | Forme medicamenteuse orale, solide et concue pour eviter le mesusage | |
HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
TR200101929T2 (tr) | Geliştirilmiş kararlılığa sahip bileşimler. | |
TR200101928T2 (tr) | Geliştirilmiş kararlılığa sahip bileşimler | |
CR20210318A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 9/48, A61K 47/10, A61P 11/00 Ipc: A61K 9/48 (2011.01), A61K 47/10 (2011.01), A61P 11 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10, 13, E 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |